Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Blood (2016) 128 (22): 3307.

https://doi.org/10.1182/blood.V128.22.3307.3307

Published: 2016

Journal Articles

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Maria-Victoria Mateos, MD PhD, Miguel-T Hernandez, Pilar Giraldo, MD PhD, Javier De La Rubia, Felipe De Arriba, Lucia Lopez-Corral, Laura Rosiñol, Bruno Paiva, PhD, Luis Palomera, MD PhD, Joan Bargay, MD, Albert Oriol, Felipe Prosper, MD, Javier Lopez, Sr., MD PhD, Jose-María Arguiñano, Nuria Quintana, Jose Luis Garcia, Joan Bladé, Juan José Lahuerta, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 3308.

https://doi.org/10.1182/blood.V128.22.3308.3308

Published: 2016

Journal Articles

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Blood (2016) 128 (22): 3436.

https://doi.org/10.1182/blood.V128.22.3436.3436

Published: 2016

Journal Articles

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Beatriz Sanchez-Vega, PhD, Rafael Alonso, MD, Isabel Cuenca, Santiago Barrio, PhD, Yanira Ruiz-Heredia, Carlos Marin, Inmaculada Rapado, PhD, Cristina Jimenez, BSc, Xabier Aguirre, Rosa M. Ayala, MD PhD, Teresa Cedena, Bruno Paiva, PhD, Maria-Victoria Mateos, MD PhD, Laura Rosiñol, Joan Bladé, Jesus San Miguel, MD PhD, Ramon Garcia-Sanz, MD PhD, Juan José Lahuerta, MDPhD, Joaquín Martínez-López, MD PhD

Blood (2016) 128 (22): 3283.

https://doi.org/10.1182/blood.V128.22.3283.3283

Published: 2016

Journal Articles

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

Bruno Paiva, PhD, Sarah K. Johnson, PhD, Maria-Victoria Mateos, MD PhD, Daisy V. Alapat, MD, Noemi Puig, MD PhD, Miguel-T Hernandez, Fernando Escalante, Alfonso Garcia de Coca, MD PhD, Joan Bladé, Juan Jose Lahuerta, Quentin Lecrevisse, Jacques J.M. van Dongen, MD PhD, Alberto Orfao, MD PhD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 373.

https://doi.org/10.1182/blood.V128.22.373.373

Published: 2016

Journal Articles

New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)

Laura Moreno, Aintzane Zabaleta, Diego Alignani, Marta Lasa, Patricia Maiso, PhD, Tomas Jelinek, MD, Victor Segura, PhD, Jose Antonio Delgado, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Klaus Strein, MD PhD, Minh Diem Vu, PhD, Jesus San Miguel, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 2096.

https://doi.org/10.1182/blood.V128.22.2096.2096

Published: 2016

Journal Articles

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)

Laura Moreno, Aintzane Zabaleta, Diego Alignani, Daniel Ajona, Marta Lasa, Patricia Maiso, PhD, Tomas Jelinek, MD, Victor Segura, PhD, Jose Antonio Delgado, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Jesus San Miguel, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 2105.

https://doi.org/10.1182/blood.V128.22.2105.2105

Published: 2016

Journal Articles

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

Blood (2016) 128 (22): 2078.

https://doi.org/10.1182/blood.V128.22.2078.2078

Published: 2016

Journal Articles

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

Paula Arana, Aintzane Zabaleta, Marta Lasa, Patricia Maiso, PhD, Diego Alignani, Tomas Jelinek, MD, Victor Segura, PhD, Wouter van den Bossche, Cristina Teodosio, Daniela Damasceno, Paula Rodriguez-Otero, MD PhD, Felipe Prosper, MD, Maria-Victoria Mateos, MD PhD, Juan Jose Lahuerta, Joan Bladé, Jacques J.M. van Dongen, MD PhD, Jesus San Miguel, MD PhD, Alberto Orfao, MD PhD, Bruno Paiva, PhD

Blood (2016) 128 (22): 482.

https://doi.org/10.1182/blood.V128.22.482.482

Published: 2016

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Hervé Avet-Loiseau, Tineke Casneuf, Christopher Chiu, PhD, Jacob P. Laubach, MD, Je-Jung Lee, Philippe Moreau, Torben Plesner, Professor, Hareth Nahi, Nushmia Z Khokhar, Ming Qi, Jordan Schecter, Victoria Carlton, PhD, Xiang Qin, Kevin Liu, Kaida Wu, MD PhD, Sen H. Zhuang, MD, PhD, Tahamtan Ahmadi, MD, A. Kate Sasser, PhD, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 246.

https://doi.org/10.1182/blood.V128.22.246.246

Published: 2016

Journal Articles

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

Blood (2016) 128 (22): 801.

https://doi.org/10.1182/blood.V128.22.801.801

Published: 2016

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MD PhD, Cristina Motlló, MD, Paula Rodriguez-Otero, MD PhD, Joaquín Martínez-López, MD PhD, Javier De La Rubia, Mieke Ptaszynski, Brian Tunquist, Ramon Garcia-Sanz, MD PhD, Albert Oriol, Juan José Lahuerta, MD PhD, Jesús San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD

Blood (2016) 128 (22): 4503.

https://doi.org/10.1182/blood.V128.22.4503.4503

Published: 2016

Journal Articles

Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma

Arantxa Carrasco, Teresa Ezponda, Cem Meydan, PhD, Marta Kulis, Raquel Ordoñez, Leire Garate, Victor Segura, PhD, Diego Alignani, Bruno Paiva, PhD, Jesus San Miguel, MD PhD, José I. Martin Subero, PhD, Ari Melnick, MD, Felipe Prosper, MD, Xabier Agirre, PhD

Blood (2016) 128 (22): 4420.

https://doi.org/10.1182/blood.V128.22.4420.4420

Published: 2016

Journal Articles

Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM)

Gabriel Bretones, Bruno Paiva, PhD, Rafael Valdes-Mas, Diego Alignani, Miguel Garcia, Leire Burgos, Diana Alvarez Puente, Xabier Agirre, PhD, Felipe Prosper, MD, Carlos Lopez-Otin, Jesus San Miguel, MD PhD

Blood (2016) 128 (22): 4442.

https://doi.org/10.1182/blood.V128.22.4442.4442

Published: 2016

Journal Articles

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Jesus San Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Jatin J. Shah, MD, Enrique M. Ocio, MD PhD, Paula Rodriguez-Otero, MD PhD, Donna Reece, MD, Nikhil C. Munshi, MD, David Avigan, MD, Yang Ge, PhD, Arun Balakumaran, MD PhD SM, Patricia Marinello, PharmD, Robert Z. Orlowski, MD PhD, David Siegel, MD PhD

Blood (2015) 126 (23): 505.

https://doi.org/10.1182/blood.V126.23.505.505

Published: 2015

Journal Articles

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Juan A Flores-Montero, MD, Bruno Paiva, PhD, Luzalba Sanoja-Flores, M.Sc., Noemi Puig, MD PhD, Omar García, PhD, Sebastian Böttcher, MD PD, José J Pérez-Morán, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia-Sanz, MD PhD, Cristina Jimenez, BsC, Marcos González, MD PhD, Joaquin Martinez-López, MD PhD, María Consuelo Cañizo, MD PhD, Jesus San Miguel, MD PhD, Brian Durie, MD, Jacques J.M. van Dongen, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 367.

https://doi.org/10.1182/blood.V126.23.367.367

Published: 2015

Journal Articles

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2015) 126 (23): 2963.

https://doi.org/10.1182/blood.V126.23.2963.2963

Published: 2015

NARROW

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

Sustained Overall Survival Benefit with Lenalidomide Plus Dexamethasone Versus No Treatment in Patients with Smoldering Myeloma at High Risk of Progression to Myeloma: Long Term Analysis

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients

Automated Multiparameter Flow Cytometry (MFC) Immunophenotyping for Reproducible Identification of High Risk Smoldering Multiple Myeloma (SMM)

New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)

Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)

Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial

High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Non-Invasive Genetic Profiling Is Highly Applicable in Multiple Myeloma (MM) through Characterization of Circulating Tumor Cells (CTCs)

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Long Non-Coding RNAs Annotation and Their Involvement in Multiple Myeloma

Genomic Profiles of Bone Marrow (BM) Clonal Plasma Cells (PCs) Vs Circulating Tumor Cells (CTCs) and Extramedullary (EM) Plasmacytomas in Multiple Myeloma (MM)

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only